Direct Oral Anticoagulants Versus Traditional Anticoagulation in Cirrhotic Patients with Portal Vein Thrombosis: Updated Systematic Review
Clinical and Applied Thrombosis/Hemostasis · 2024-01 · 30
DOI: 10.1177/10760296241303758 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Clinical and Applied Thrombosis/Hemostasis, online erschienen am 26.11.2024. Verfasst von Xiulin Xiao und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatopancreatobiliary Surgery, Ganzhou People's Hospital, Ganzhou, Jiangxi, China. Hauptthemen laut MEDLINE: Liver Cirrhosis, Anticoagulants, Venous Thrombosis, Portal Vein. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
This systematic review aimed to evaluate the comparative effectiveness and safety of direct oral anticoagulants (DOACs) compared to traditional anticoagulation (vitamin K antagonists or low-molecular-weight heparins) in cirrhotic patients with portal vein thrombosis (PVT).
Methods
We conducted a literature search in PubMed and Embase databases up to May 2024. Studies were selected according to the PICOS criteria, focusing on cirrhotic patients with PVT treated with DOACs (dabigatran, rivaroxaban, apixaban, or edoxaban) compared to traditional anticoagulation.
Results
Our systematic review included four observational studies conducted in Japan, China, and the United States, involving a total of 223 patients with cirrhosis and PVT. The included studies collectively suggested that anticoagulation therapy, including DOACs, was associated with improved recanalization rates and reduced progression of PVT in patients with liver cirrhosis, without a significant increase in bleeding complications. Specifically, edoxaban demonstrated superior effectiveness in reducing PVT volume compared to traditional anticoagulation, while maintaining a favorable safety profile.
Conclusion
DOACs may provide a promising therapeutic option for PVT in cirrhotic patients. Further research is needed to confirm the potential benefits and risks of DOACs in this population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepatopancreatobiliary Surgery, Ganzhou People's Hospital, Ganzhou, Jiangxi, China.
- Department of Cardiology, the First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
ORCID-Profile: Wengen Zhu
Zitieren
APA
Xiao, X., Zhu, W., & Dai, Q. (2024). Direct Oral Anticoagulants Versus Traditional Anticoagulation in Cirrhotic Patients with Portal Vein Thrombosis: Updated Systematic Review. Clinical and Applied Thrombosis/Hemostasis, 30. https://doi.org/10.1177/10760296241303758
Vancouver
Xiao X, Zhu W, Dai Q. Direct Oral Anticoagulants Versus Traditional Anticoagulation in Cirrhotic Patients with Portal Vein Thrombosis: Updated Systematic Review. Clinical and Applied Thrombosis/Hemostasis. 2024;30. doi:10.1177/10760296241303758
BibTeX
@article{Xiao2024,
author = {Xiao, Xiulin and Zhu, Wengen and Dai, Qixin},
title = {Direct Oral Anticoagulants Versus Traditional Anticoagulation in Cirrhotic Patients with Portal Vein Thrombosis: Updated Systematic Review},
journal = {Clinical and Applied Thrombosis/Hemostasis},
year = {2024},
volume = {30},
doi = {10.1177/10760296241303758}
}
EUVIMED